Meta-analysis of randomized controlled trials on the efficacy and safety of intracoronary administration of tirofiban for no-reflow phenomenon

BMC Cardiovascular Disorders

Volumn 13, Issue , 2013, Pages

  Qin, Tao ^a   Xie, Lu ^b   Chen, Meng Hua ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^b GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; GLYCERYL TRINITRATE; NITROPRUSSIDE SODIUM; TIROFIBAN; VERAPAMIL; ANTITHROMBOCYTIC AGENT; TYROSINE;

ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HUMAN; INTRACORONARY DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; META ANALYSIS; NO REFLOW PHENOMENON; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; ANALOGS AND DERIVATIVES; CORONARY BLOOD VESSEL; DRUG EFFECTS; INTRAARTERIAL DRUG ADMINISTRATION; NO-REFLOW PHENOMENON; TREATMENT OUTCOME;

CORONARY VESSELS; HUMANS; INJECTIONS, INTRA-ARTERIAL; NO-REFLOW PHENOMENON; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; TYROSINE;

EID: 84883664912     PISSN: None     EISSN: 14712261     Source Type: Journal    
DOI: 10.1186/1471-2261-13-68     Document Type: Article

References (43)

1. Vallejo E, Pena D, Norono O, Ban Hayashi E, Gaspar J, Villavicencio R, Martinez Rios MA. The slow-reflow phenomenon: its incidence and clinical characteristics in aseries of cases. Arch Inst Cardiol Mex 1998, 68:247-252.
2. Morishima I, Sone T, Okumura K, Okumura K, Tsuboi H, Kondo J, Mukawa H, Matsui H, Toki Y, Ito T, Hayakawa T. Ngiographic slow-reflow phenomenon: as a predictor of adverse long term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol 2000, 36:1202-1209. 10.1016/S0735-1097(00)00865-2, 11028471.
3. Brosh D, Assali AR, Mager A, Porter A, Hasdai D, Teplitsky I, Rechavia E, Fuchs S, Battler A, Kornowski R. Effect of no-reflow during primary percutaneous coronary intervention for acute myocardial infarction on six-month mortality. Am J Cardiol 2007, 99:442-445. 10.1016/j.amjcard.2006.08.054, 17293180.
4. Ramjane K, Han L, Jin C. The diagnosis and treatment of the no-reflow phenomenon in patients with myocardial infarction undergoing percutaneous coronary intervention. Exp Clin Cardiol 2008, 13:121-128. 2586408, 19343126.
5. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions 2008, London: Wiley Interscience.
6. Chen SF, Liu HM, Li YS. Efficacy and safety of intracoronary tirofiban on noreflow patients after PCI in acute coronary syndrome. Tianjin Pharm 2012, 24:18-20.
7. Fu W. Effects of tirofiban in elder patients of acute myocardial infarction with noreflow phenomenon during PCI. Chin J Gerontol 2012, 8:1565-1567.
8. Guan XS. The clinical impact of tirofiban on slow flow or no-reflow of post-PCI in patients with acute myocardial infarction. Chin J of Med Guide 2012, 14:268,243.
9. He DM, Huang JZ. The efficacy and safety of tirofiban for no-reflow phenomenon in acute coronary syndrome during PCI. Chin Community Doctors 2012, 7:56-57.
10. Luan B, Han YL, Jing QM, Jing QM, Wang SL, Ma YY, Wang G, Wang B. Efficacy of intracoronary administration of tirofiban for no-reflow during emergency PCI. Shenyang Army Med 2007, 20:367-369.
11. Wang YP, Ding MX, Zhao SW. Clinical observation of tirofiban treatment on no-flow phenomenon in patients with acute ST-elevation myocardial infarction during percutaneous coronary intervention. Tianjin Med J 2012, 40:159-160.
12. Wei L, Li XQ, Jin EZ, Wang XY. Efficacy and safety of intracoronary tirofiban on no-ref low pati phenomenon after percutaneous coronary intervention. J Clin Cardiol (China) 2011, 27:25-29.
13. Wu J, Xu L, Du H, Wang YR. Influence of tirofiban on no-reflow after percutaneous coronary intervention in patients with acute coronary syndrome. Chin J Evid Based Cardiovasc Med 2012, 14:131-133.
14. Zhang HY, Wang PX, Cao YJ, Wu ZG, Liu HS. Clinical study of intracoronary injections of tirofiban in acute myocardial infarction patients with no reflow phenomenon after percutaneous coronary intervention. J Clin Cardiol (China) 2011, 27:25-29.
15. Zhang J, Jiang JG. Effects of intracoronary injections of tirofiban in acute coronary syndrome patients with no reflow phenomenon after percutaneous coronary intervention. Anhui Med J 2012, 2:155-158.
16. Piana RN, Paik GY, Moscucci M, Cohen DJ, Gibson CM, Kugelmass AD, Carrozza JP, Kuntz RE, Baim DS. Incidence and treatment of 'no-reflow' after percutaneous coronary intervention. Circulation 1994, 89:2514-2518. 10.1161/01.CIR.89.6.2514, 8205658.
17. Niccoli G, Burzotta F, Galiuto L, Crea F. Myocardial no-reflow in humans. J Am Coll Cardiol 2009, 54:281-292. 10.1016/j.jacc.2009.03.054, 19608025.
18. Chen YF, Yang YJ. No-reflow phenomenon after percutaneous coronary intervention. Adv Cardiovasc Dis Jan 2005, 26:4-8.
19. Rittersma SZ, van der Wal AC, Koch KT, Piek JJ, Henriques JP, Mulder KJ, Ploeqmakers JP, Meesterman M, de Winter RJ. Plaque instability frequently occurs days or weeks before occlusive coronary thrombosis. Circulation 2005, 111:1160-1165. 10.1161/01.CIR.0000157141.00778.AC, 15723983.
20. Movahed MR, Butman SM. The pathogenesis and treatment of no-reflow occurring during percutaneous coronary intervention. Cardiovasc Revase Med 2008, 9:56-61.
21. Lee CH, Wong HB, Tan HC, Zhang JJ, Teo SG, Ong Low A, Sutandar A, Lim YT. Impact of reversibility of no reflow phenomenon on 30-day mortality following percutaneous revascularization for acute myocardial infarction-insights from a 1,328 patient registry. J Interv Cardiol 2005, 18:261-266. 10.1111/j.1540-8183.2005.00041.x, 16115155.
22. Pan W, Wang LF, Yu JH, Fan Y, Yang SS, Zhou LJ, Li Y, Li WM. Intracoronary nitroprusside in the prevention of the no-reflow phenomenon in acute myocardial infarction. Chin Med J 2009, 122:2718-2723.
23. Zhao HY. Effects of adenosine in reperfusion of acute myocardial infarction. China PracMed 2009, 4:71-72.
24. Resnic FS, Wainstein M, Lee MK, Behrendt D, Wainstein RV, Ohno-Machado L, Kirshenbaum JM, Rogers CD, Popma JJ, Piana R. No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. Am Heart J 2003, 145:42-46. 10.1067/mhj.2003.36, 12514653.
25. Kaplan BM, Benzuly KH, Kinn JW, Bowers TR, Tilli FV, Grines CL, O'Neill WW, Safian RD. Treatment of no-reflow in degenerated saphenous vein graft interventions: comparison of intracoronary verapamil and nitroglycerin. Cathet Cardiovasc Diagn 1996, 39:113-118. 10.1002/(SICI)1097-0304(199610)39:2<113::AID-CCD1>3.0.CO;2-I, 8922307.
26. Michaels AD, Appleby M, Otten MH, Dauterman K, Ports TA, Chou TM, Gibson CM. Pretreatment with intragraft verapamil prior to percutaneous coronary intervention of saphenous vein graft lesions: results of the randomized, controlled vasodilator prevention on no reflow (VAPOR) trial. J Invasive Cardiol 2002, 14:299-302.
27. Oldenburg O, Eggebrecht H, Herrmann J, Naber CK, Haude M, Erbel R, Baumgart D. Dose-dependent effects of in tracoronary verapamil on systemic and coronary hemodynamics. Cardiovasc Drugs Ther 2000, 14:651-655. 10.1023/A:1007823116491, 11300366.
28. Ishihara M, Sato H, Tateishi H, Kawagoe T, Shimatani Y, Ueda A, Kurisu S. Effects of various doses of intracoronary diltiazem on coronary resistance vessels in humans. Jpn Circ J 1995, 5912:790-798.
29. Huang D, Qian J, Ge L, Jin X, Jin H, Ma J, Liu Z, Zhang F, Dong L, Wang X, Yao K, Ge J. REstoration of coronary flow in patients with no-reflow after primary coronary intervention of acute myocardial infarction (RECOVER). Am Heart J 2012, 164:394-401. 10.1016/j.ahj.2012.06.015, 22980307.
30. Topol EJ, Byzova TV, Plow EF. Platelet GPIIb-IIIa blockers. Lancet 1999, 353:227-231. 10.1016/S0140-6736(98)11086-3, 9923894.
31. Warnhol A, Ostad MA, Heitzer T, Goldmann BU, Nowak G, Munzel T. Effect of tirofiban on percutaneous coronary intervention-induced endothelial dysfunction in patients with stable coronary artery disease. Am J Cardiol 2005, 95:20-23.
32. Stangl PA, Lewis S. Review of currently available GP IIb/IIIa inhibitors and their role in peripheral vascular interventions. Semin Intervent Radiol 2010, 27:412-421. 10.1055/s-0030-1267856, 3324199, 22550383.
33. Kouz R, Kouz S, Schampaert E, Rinfret S, Tardif JC, Nguyen M, Eisenberg M, Harvey R, Afilalo M, Lauzon C, Dery JP, Mansour S, Huynh T. Effectiveness and safety of glycoprotein IIb/IIIa inhibitors in patients with myocardial infarction undergoing primary percutaneous coronary intervention: a meta-analysis of observational studies. Int J Cardiol 2011, 153:249-255. 10.1016/j.ijcard.2010.08.019, 20971515.
34. Kimmelstiel C, Badar J, Covic L, Waxman S, Weintraub A, Jacques S, Kuliopulos A. Pharmacodynamics and pharmacokinetics of the platelet GPIIb /IIIa inhibitor tirofiban in patients undergoing percutaneous coronary intervention: implications for adjustment of tirofiban and clopidogrel dosage. Thromb Res 2005, 116:55-66. 10.1016/j.thromres.2004.11.011, 15850609.
35. Zhang WZ, Song MC, Liang JY, Li JH, Lei HD, Su JQ, Chen GQ. Effects of tirofiban in patients with no reflow during PCI procedure. South China J Cardiovasc Dis 2008, 14:103-105.
36. Geeganage C, Wilcox R, Bath PMW. Triple antiplatelet therapy for preventing vascular events: a systematic review and meta-analysis[J]. BMC Med 2010, 8:36. 10.1186/1741-7015-8-36, 2893089, 20553581.
37. Hamada S, Nishiue T, Nakamura S, Sugiura T, Kamihata H, Miyoshi H, Imuro Y, Iwasaka T. TIMI frame count immediately after primary coronary angioplasty as a predictor of functional recovery in patients with TIMI 3 reperfused acute myocardial infarction[J]. J Am Coll Cardiol 2001, 38(3):666-671. 10.1016/S0735-1097(01)01424-3, 11527614.
38. Rezkalla SH, Kloner RA. Coronary no-reflow phenomenon: from the experimental laboratory to the cardiac catheterization laboratory[J]. Catheter Cardiovasc Interv 2008, 72(7):950-957. 10.1002/ccd.21715, 19021281.
39. Ndrepepa G, Tiroch K, Keta D, Fusaro M, Seyfarth M, Pache J, Mehilli J, Schomig A, Kastrati A. Predictive factors and impact of no reflow after primary percutaneous coronary intervention in patients with acute myocardial infarction[J]. Circ Cardiovasc Interv 2010, 3(1):27-33. 10.1161/CIRCINTERVENTIONS.109.896225, 20118156.
40. Stone GW, Brodie BR, Griffin JJ, Morice MC, Costantini C, Goar FST, Overlie PA, Popma JJ, McDonnell J, Jones D, O'Neill WW, Grines CL. Prospective, multicenter study of the safety and feasibility of primary stenting in acute myocardial infarction: in-hospital and 30-Day results of the PAMI stent pilot trial J]. J Am Coll Cardiol 1998, 31(1):23-30. 10.1016/S0735-1097(97)00439-7, 9426013.
41. Van't Hof AW, Liem A, Suryapranata H, Hoorntje JC, De Boer MJ, Zijlstra F. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction myocardial blush grade[J]. Circulation 1998, 97(23):2302-2306. 10.1161/01.CIR.97.23.2302, 9639373.
42. Henriques JP, Zijlstra F, Van't Hof AW, De Boer MJ, Dambrink JH, Gosselink M, Hoorntje JC, Suryapranata H. Angiographic assessment of reperfusion in acute myocardial infarction by myocardial blush grade[J]. Circulation 2003, 107(16):2115-2119. 10.1161/01.CIR.0000065221.06430.ED, 12695301.
43. Stone GW, Peterson MA, Lansky AJ, Dangas G, Mehran R, Leon MB. Impact of normalized myocardial perfusion after successful angioplasty in acute myocardial infarction[J]. J Am Coll Cardiol 2002, 39(4):591-597. 10.1016/S0735-1097(01)01779-X, 11849856.